Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
acid, adolescent, advice, alia, Alzheimer, Aurobindo, back, began, Beta, Boehringer, channel, CHMP, clarify, collaborative, comparison, counterpart, CSO, Deloitte, Department, Dicerna, direct, direction, disagreement, disclaimer, dismissed, DMCC, EMA, Endocrinology, endorsed, ESG, FDI, fermentation, forecasted, fourth, Germany, Glaxo, hand, Hospital, Hotline, Icosema, Ingelheim, interference, Lange, letter, longer, Mackay, mandatory, Martin, mathematical, methodology, MHRA, modestly, modified, newly, operationally, OSI, outpatient, overweight, overwhelming, Oxford, platform, Poulsen, preliminary, principle, procedure, proffered, Prosidion, purification, PwC, quantify, recovery, RESERVED, restore, reversal, reverse, ribonucleic, Rio, RNAi, rollout, rotation, royalty, satisfaction, Schindler, scope, screening, submission, Sun, Sweden, syringe, system, unbilled, uninsured, University, vaccination, valuation, Wegovy, whistleblowing, written, yearly
Removed:
affiliate, applied, Astra, billed, Brexit, CAD, carried, central, Chairmanship, CNY, creating, CV, delivered, DEVOTE, discontinued, EUR, exit, expert, GBP, hedge, Hewitt, hypoglycaemia, IDegLira, Inflation, interim, invest, JPY, Latin, lease, Liz, low, lower, modest, Nationalbank, notify, penetration, preference, recurring, showed, successful, TABULAR, withdrawal, writing, Zeneca
Filing tables
Filing exhibits
Associated NVO transcripts
NVO similar filings
Filing view
External links
Exhibit 15.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-221244 and 333-222923 on Form S-8 of our reports dated February 2, 2022 relating to the financial statements of Novo Nordisk A/S and the effectiveness of Novo Nordisk A/S’s internal control over financial reporting appearing in this Annual Report on Form 20-F for the year ended December 31, 2021.
/s/ Deloitte Statsautoriseret Revisionspartnerselskab
Copenhagen, Denmark
February 2, 2022